DFN 15

Drug Profile

DFN 15

Alternative Names: DFN-15A; DFN-15B

Latest Information Update: 16 Feb 2017

Price : $50

At a glance

  • Originator Promius Pharma
  • Developer Dr Reddys Laboratories
  • Class Antimigraines
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Migraine

Most Recent Events

  • 01 Dec 2016 Dr. Reddy's Laboratories initiates a phase III trial for Migraine in USA (PO) (NCT03009019)
  • 01 Dec 2016 Phase-III clinical trials in Migraine in USA (PO) (NCT03006276)
  • 01 Jun 2016 Dr. Reddy's Laboratories completes a phase II trial for Migraine in USA (NCT02472418)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top